PL9643 shows promise in dry eye disease treatment

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a small-cap biotech currently valued at $5.46 million, has announced updated results from Phase 3 clinical trials for PL9643, a potential new treatment for dry eye disease (DED), which show the drug achieving statistically significant symptom resolution across multiple endpoints. These findings suggest PL9643 could offer a more effective option for the millions suffering from this condition. According to InvestingPro data, while the company’s stock has faced significant pressure recently, its current price suggests potential undervaluation based on Fair Value analysis.

The MELODY-1 trial, completed last year, involved 575 patients and demonstrated that PL9643 was well-tolerated and provided significant symptom relief. Notably, six of the thirteen symptom endpoints showed a significantly higher percentage of patients achieving complete symptom resolution with PL9643 compared to a placebo after 12 weeks of treatment. InvestingPro analysis reveals the company holds more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn - crucial factors for investors monitoring clinical development progress.

Early symptom improvement was evident from week two and continued through week 12 without signs of plateauing, contrasting with the minimal and short-lived improvement seen in placebo-treated patients. These results align with the FDA’s 2020 guidance on responder analyses for dry eye drug development, which recommends demonstrating a statistically significant difference in the percentage of patients achieving complete symptom resolution.

Palatin’s Chief Medical Officer, Dr. Michael Raizman, highlighted the significance of the Symptom Composite Score improvements, indicating a meaningful patient benefit. The company’s President and CEO, Dr. Carl Spana, emphasized PL9643’s rapid onset of efficacy and excellent safety profile, positioning it as a potentially best-in-class therapy for DED.

Palatin is currently discussing collaboration opportunities, aiming to finalize a deal in the second half of this year, which could lead to further clinical trials and eventual FDA approval. With analysts setting a target price significantly above current levels, these developments could be crucial for the company’s future. The dry eye disease market is estimated to reach $7.46 billion by 2029, underscoring the significant commercial potential for effective new treatments like PL9643. For deeper insights into Palatin’s financial health and growth prospects, including 13 additional ProTips, check out the comprehensive research available on InvestingPro.

This update is based on a press release statement from Palatin Technologies, Inc. and provides a glimpse into the promising future of dry eye disease therapy.

In other recent news, Palatin Technologies, Inc. reported promising results from its Phase 2 obesity study, demonstrating significant weight loss with the combination of bremelanotide and tirzepatide. The study achieved a statistically significant reduction in weight, with patients experiencing an average weight loss of 4.4% compared to 1.6% in the placebo group. Additionally, Palatin announced positive findings from its Phase 2b study on Type 2 diabetic nephropathy, where 71% of participants achieved a greater than 30% reduction in urine protein to creatinine ratio, indicating reduced kidney damage. In parallel, Palatin is contesting a delisting notice from the NYSE American due to non-compliance with stockholders’ equity requirements. The company is appealing this decision, which allows its stock to remain actively traded during the process. Efforts to regain compliance include accelerating licensing discussions and advancing equity financing negotiations. Palatin remains committed to addressing the listing requirements and establishing a stronger financial foundation. These developments reflect ongoing efforts by Palatin to advance its medical treatments and maintain its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.